HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a price target of $3. This reaffirmation of the company's stock rating and price target suggests continued confidence in Sangamo's prospects.
January 19, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Sangamo Therapeutics with a maintained price target of $3, indicating a positive outlook on the company's stock.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can have a positive impact on investor sentiment and potentially lead to a short-term increase in the stock price. The confidence in the company's prospects by the analyst is likely to be viewed favorably by the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100